Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new scientific data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, LA. The company's presentations include one oral session and two poster presentations that highlight recent scientific advances and underscore the therapeutic potential of Siren's AAV-based immuno-gene therapy platform across solid tumor indications.
Presentation details:
Oral Presentation:
SRN-101 Universal AAV Gene Therapy for Solid Tumors. Dr. Nicole K. Paulk, CEO, Founder, President, Siren Biotechnology May 17, 2025 | 8:00am CST
Poster Presentations:
Vectorized Interferons Provide a Robust and Sustained Transcriptional Response Over Traditional Non-Vectorized Recombinant Cytokine Therapies in Human High-Grade Glioma Cells. Justin Lee, BS, Preclinical Associate Scientist May 14, 2025 | 5:30 – 7:00pm CST
Identification of Pharmacologically Relevant Species for IND-Enabling Toxicology Studies by Deep Comparative Transcriptomic Profiling of PBMCs Treated with Recombinant Human Payloads. Christopher Lovejoy, MS, Preclinical Associate Scientist May 14, 2025 |5:30 – 7:00pm CST
'We're excited to share our latest data with the scientific community at ASGCT, which remains the most prestigious venue for showcasing gene therapy innovations,' said Dr. Nicole K. Paulk, PhD, Siren Biotechnology's CEO and Founder. 'These presentations reflect our continued progress advancing our Universal AAV Immuno-Gene Therapy Platform and our commitment to developing transformative therapies to treat solid tumor cancers.'
About Siren Biotechnology Headquartered in San Francisco, CA, Siren Biotechnology is sounding the alarm against cancer. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer.
To learn more, visit sirenbiotechnology.com, and follow us on LinkedIn, Twitter, Facebook and Instagram.
Universal AAV Immuno-Gene Therapy for Cancer. It's Here.
CONTACT: Contact Akela Kuwahara press@sirenbiotechnology.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

New York Post

3 hours ago

• New York Post

News Corp extends CEO Robert Thomson's contract through 2030

News Corp will extend the contract of chief executive Robert Thomson through 2030, the media giant said Sunday. Thomson was appointed CEO of News Corp — whose properties include The Post, Dow Jones, the Wall Street Journal and book publisher HarperCollins — in 2013. His contract was extended in 2023 until 2027. He has delivered News Corp's four most profitable years from fiscal 2021 to 2024, with continued strong performance in fiscal 2025 despite a challenging media landscape, the company said. 3 News Corp CEO Robert Thomson had his contract extended through 2030. Bloomberg via Getty Images 'Robert has been instrumental in News Corp's growth and transformation, and his vision and leadership are extremely important as the company continues to navigate this era of rapid change,' News Corp Chair Lachlan Murdoch said in a statement. Thomson has been at the helm of the New York-based company through several major deals, such as the sale of its Australian cable-TV unit Foxtel to British-owned sports network DAZN for $2.19 billion in 2024. 3 New York-based News Corp is the parent company of The Post. Robert Miller 3 News Corp's properties include The Post, Dow Jones, the Wall Street Journal and book publisher HarperCollins. Bloomberg via Getty Images News Corp also signed landmark agreements with major technology platforms, including most recently with OpenAI, to license the company's intellectual property in exchange for meaningful compensation. 'Rupert and Lachlan Murdoch have adroitly sculpted a company that is passionate and principled and purposeful, and it is a profound privilege to serve as Chief Executive,' Thomson said in a statement. 'For journalists, for authors, for society, for those who strive and aspire, these are times of immense challenge and boundless opportunity. Our leadership team is acutely conscious of an unwavering responsibility to our shareholders, and we are grateful for the sterling efforts of all our colleagues as we pursue profitability and seek to realize our vast potential.'

Business Insider

5 hours ago

• Business Insider

Upcoming Stock Splits This Week (June 23 to June 27)

These are the upcoming stock splits for the week of June 23 to June 27, based on TipRanks' Stock Splits Calendar. A stock split takes place when a company increases its number of outstanding shares by issuing more to existing shareholders, effectively reducing the price per share without altering the firm's overall market capitalization. While the underlying value remains the same, the lower share price makes the stock more accessible to everyday investors and may help boost market interest. Confident Investing Starts Here: Meanwhile, a reverse stock split does the opposite, shrinking the share count by consolidating existing shares into fewer units. This pushes the stock price higher while keeping the total valuation the same. It's a common move for companies trying to meet exchange listing requirements, especially if their share price is flirting with minimum thresholds like those set by the Nasdaq. Whether it's about attracting more investors or holding onto a listing, these corporate actions can offer valuable clues about a company's strategy and where it sees itself heading next. Let's take a look at the upcoming stock splits for the week. Pegasystems (PEGA) – Pegasystems is a leading provider of enterprise AI-powered decisioning and workflow automation software. On June 17, the company announced a 2-for-1 forward stock split, aimed at improving share accessibility for retail investors. PEGA stock is expected to begin trading on a split-adjusted basis on June 23. TruGolf Holdings (TRUG) – Specializing in high-end golf simulator technology, TruGolf aims to bring the driving range indoors. On June 18, the company announced a 1-for-50 reverse stock split to help maintain compliance with Nasdaq's listing requirements. The split is set to take effect on June 23. Maase (MAAS) – China-based Maase, a digital platform company, is switching from trading American Depositary Shares (ADSs) to listing its regular shares directly on the Nasdaq. To prepare for this transition, the company announced a 1-for-90 reverse stock split on June 18, meaning every 90 ADSs will be converted into one regular share. The split takes effect when the market opens on June 23, 2025. Super League Enterprise (SLE) – Super League builds immersive experiences across gaming and metaverse platforms. On June 18, the company announced a 1-for-40 reverse stock split, designed to boost the share price and extend its Nasdaq listing runway. The stock will begin trading on a split-adjusted basis on June 23. KULR Technology Group (KULR) – Focused on thermal management and battery safety for aerospace and EV markets, KULR announced a 1-for-8 reverse stock split on June 13 to regain compliance with Nasdaq's minimum bid price rule. The stock will begin trading on a split-adjusted basis on June 23. Stem, Inc. (STEM) – Leveraging AI to boost grid-scale energy efficiency, Stem announced a 1-for-20 reverse stock split on June 11 to comply with the NYSE's minimum bid price requirement. The stock will begin trading on a split-adjusted basis on June 23. Cellectar Biosciences (CLRB) – Cellectar is a clinical-stage biotech developing phospholipid drug conjugates for targeted cancer treatment. On June 18, the company announced a 1-for-30 reverse stock split, following shareholder approval the prior week. The move is aimed at regaining compliance with Nasdaq's minimum bid price requirement. The split is slated to go into effect on June 24. Jiade Limited (JDZG) – China-based Jiade Limited, which focuses on adult education and logistics services, announced on June 20 that it would implement a 1-for-8 reverse stock split, effective June 24, consolidating its shares and updating its CUSIP to regain compliance with Nasdaq's minimum bid price requirement.

Business Upturn

5 hours ago

• Business Upturn

WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On February 5, 2025, Grizzly Research published a report entitled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud.' Grizzly stated that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue.' On this news, On this news, GeneDx's stock fell $4.84 per share, or 6.7%, to close at $67.18 per share on February 5, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]